前立腺がん核医学診断薬の世界市場レポート 2025年

前立腺がん核医学診断薬市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は14.6％で、17億1,000万米ドルに成長します。予測期間の成長は、前立腺がんの有病率上昇、ポジトロン断層撮影の需要増加、環境の持続可能性に関する意識の高まり、がんの頻度上昇、デジタル変革の進展に起因しています。予測期間の主な動向には、製品イノベーション、技術進歩、核医学イメージングにおける進歩、放射性医薬品とイメージング方法の改良、革新的な放射性医薬品などがあります。

前立腺がんの有病率の増加が前立腺がん核医学診断薬市場の成長を牽引すると予想されます。前立腺がんは、前立腺に発生するがんの一種です。前立腺は、男性にある小さなクルミ状の腺で、精子に栄養を与え、精液を運搬する精液の生産を担っています。前立腺がん患者の増加は、高齢化、ライフスタイルの変化、遺伝的素因などの要因によるものと考えられています。前立腺がん核医学診断薬は、ヘルスケアプロバイダーが前立腺がん患者に対して、より正確で効果的な、オーダーメイドの治療を提供するための重要な洞察を提供します。例えば、2024年2月、スイスに本部を置く世界保健機関（WHO）は、2050年までに新たに発生するがん患者は3,500万人を超え、2022年の推定2,000万人から77％増加すると予測しました。したがって、前立腺がんの有病率の増加が前立腺がん核医学診断薬市場を牽引しています。

前立腺がん核医学診断薬分野の主要企業は、画像診断技術を積極的に革新し、米国食品医薬品局（FDA）の認可を取得しています。FDAの認可は、ヘルスケアプロバイダーと患者が様々な病状に対する安全で効果的な診断検査にアクセスできることを保証します。例えば、2022年3月、スイスの製薬会社ノバルティスは、前立腺特異的膜抗原陽性（PSMA陽性）を発現する転移性去勢抵抗性前立腺がん（mCRPC）と診断された成人患者を治療するためのPluvicto（lutetium Lu 177 vipivotide tetraxetan）を発表しました。Pluvictoは、標的化合物（リガンド）と治療用放射性同位元素を組み合わせ、PSMAを発現している前立腺がん細胞に正確ながん治療を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界前立腺がん核医学診断薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の前立腺がん核医学診断薬市場：成長率分析
• 世界の前立腺がん核医学診断薬市場の実績：規模と成長, 2019-2024
• 世界の前立腺がん核医学診断薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界前立腺がん核医学診断薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の前立腺がん核医学診断薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単一光子放出コンピュータ断層撮影（SPECT）
• 光子放出コンピュータ断層撮影（PET）
• 世界の前立腺がん核医学診断薬市場テストの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予備テスト
• 確認検査
• 世界の前立腺がん核医学診断薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の前立腺がん核医学診断薬市場、SPECT（単一光子放出コンピュータ断層撮影）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ガンマカメラSPECT
• ハイブリッドSPECTまたはCT画像
• 世界の前立腺がん核医学診断薬市場陽電子放出断層撮影（PET）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PETまたはCT画像
• PETまたはMRI画像

第7章 地域別・国別分析

• 世界の前立腺がん核医学診断薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の前立腺がん核医学診断薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前立腺がん核医学診断薬市場：競合情勢
• 前立腺がん核医学診断薬市場：企業プロファイル
  • Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
  • General Electric Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GE Healthcare
• Lantheus
• CURIUM PHARMA
• Telix Pharmaceuticals Ltd.
• Eckert & Ziegler AG
• Point Biopharma Global Inc.
• Point Biopharma
• Alliance Medical Ltd.
• SHINE Medical Technologies LLC
• PETNET Solution
• NorthStar Medical Radioisotopes LLC
• Global Medical Solutions LLC
• Isotope Technologies Garching（ITG）
• Jubilant Pharma Limited
• Blue Earth Diagnostics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 前立腺がん核医学診断薬市場2029：新たな機会を提供する国
• 前立腺がん核医学診断薬市場2029：新たな機会を提供するセグメント
• 前立腺がん核医学診断薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Prostate cancer nuclear medicine diagnostics involve the utilization of radioactive substances to detect and assess prostate cancer. These diagnostics play a crucial role in the detection, staging, and management of prostate cancer by providing comprehensive functional information regarding the disease's extent and characteristics. The process entails introducing radioactive substances (radiopharmaceuticals) into the body, typically through injection, which emit gamma rays or positrons.

The primary types of prostate cancer nuclear medicine diagnostics include single photon emission computed tomography (SPECT) and positron emission tomography (PET). Single photon emission computed tomography (SPECT) is a nuclear imaging technique that generates detailed three-dimensional images depicting the body's functional processes. These diagnostics encompass various test types, including preliminary and confirmatory tests, and are utilized by various end-users such as hospitals, clinics, and others.

The prostate cancer nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer nuclear medicine diagnostics market statistics, including prostate cancer nuclear medicine diagnostics industry global market size, regional shares, competitors with a prostate cancer nuclear medicine diagnostics market share, detailed prostate cancer nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the prostate cancer nuclear medicine diagnostics industry. This prostate cancer nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.86 billion in 2024 to $0.99 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to increasing demand for pet scans, increasing urbanization, rise in disposable income, rise in need for accurate cancer diagnosis, increasing emphasis on early detection.

The prostate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to rising prevalence of prostate cancer, increasing demand for positron emission tomography, rising awareness about environmental sustainability, rising frequency of cancers, increasing digital transformation. Major trends in the forecast period include product innovation, technological advancements, advancements in nuclear medicine imaging, improved radiopharmaceuticals and imaging methods, innovative radiopharmaceuticals.

The increasing prevalence of prostate cancer is expected to drive the growth of the prostate cancer nuclear medicine diagnostics market. Prostate cancer is a type of cancer that develops in the prostate, a small, walnut-shaped gland in men responsible for producing seminal fluid that nourishes and transports sperm. The rise in prostate cancer cases can be attributed to factors such as an aging population, lifestyle changes, and genetic predisposition. Prostate cancer nuclear medicine diagnostics offer critical insights that allow healthcare providers to deliver more accurate, effective, and tailored treatment for patients with prostate cancer. For example, in February 2024, the World Health Organization, a Switzerland-based agency specializing in global public health, projected that by 2050, there will be over 35 million new cancer cases, a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of prostate cancer is driving the market for prostate cancer nuclear medicine diagnostics.

Key players in the prostate cancer nuclear medicine diagnostics sector are actively innovating diagnostic imaging technologies and securing approvals from the US Food and Drug Administration (FDA). FDA clearance ensures healthcare providers and patients have access to safe and effective diagnostic tests for various medical conditions. For example, in March 2022, Novartis, a Swiss pharmaceutical company, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) that expresses prostate-specific membrane antigen-positive (PSMA-positive). Pluvicto combines a targeting compound (ligand) with a therapeutic radioisotope, delivering precise cancer treatment to prostate cancer cells expressing PSMA.

In March 2023, Life Healthcare Group, a South African healthcare company, acquired TheraMed Nuclear to enhance its diagnostic imaging services, particularly in detecting and treating diseases such as organ dysfunction and cancer. TheraMed Nuclear, based in South Africa, specializes in prostate cancer nuclear medicine diagnostics.

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC, Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd., Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2024. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The prostate cancer nuclear medicine diagnostics market includes revenues earned by entities by bone scans, prostate-specific membrane antigen (PSMA) PET scan, bone scintigraphy, and CT scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Single Photon Emission Computed Tomography (SPECT); Photon Emission Computed Tomography (PET)
• 2) By Test Type: Preliminary Tests; Confirmatory Tests
• 3) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Single Photon Emission Computed Tomography (SPECT): Gamma Camera SPECT; Hybrid SPECT Or CT Imaging
• 2) By Positron Emission Tomography (PET): PET Or CT Imaging; PET Or MRI Imaging
• Companies Mentioned: Cardinal Health; General Electric; Bayer AG; Novartis AG; Siemens Healthineers AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Nuclear Medicine Diagnostics Market Characteristics

3. Prostate Cancer Nuclear Medicine Diagnostics Market Trends And Strategies

4. Prostate Cancer Nuclear Medicine Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Prostate Cancer Nuclear Medicine Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate Cancer Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market Growth Rate Analysis
• 5.4. Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate Cancer Nuclear Medicine Diagnostics Total Addressable Market (TAM)

6. Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

• 6.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Photon Emission Computed Tomography (SPECT)
• Photon Emission Computed Tomography (PET)
• 6.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preliminary Tests
• Confirmatory Tests
• 6.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.4. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Single Photon Emission Computed Tomography (SPECT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gamma Camera SPECT
• Hybrid SPECT Or CT Imaging
• 6.5. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Positron Emission Tomography (PET), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PET Or CT Imaging
• PET Or MRI Imaging

7. Prostate Cancer Nuclear Medicine Diagnostics Market Regional And Country Analysis

• 7.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market

• 8.1. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Nuclear Medicine Diagnostics Market

• 9.1. China Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 9.2. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Nuclear Medicine Diagnostics Market

• 10.1. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Nuclear Medicine Diagnostics Market

• 11.1. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 11.2. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Nuclear Medicine Diagnostics Market

• 12.1. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market

• 13.1. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market

• 14.1. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 14.2. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market

• 15.1. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 15.2. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Nuclear Medicine Diagnostics Market

• 16.1. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Nuclear Medicine Diagnostics Market

• 17.1. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Nuclear Medicine Diagnostics Market

• 18.1. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Nuclear Medicine Diagnostics Market

• 19.1. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Nuclear Medicine Diagnostics Market

• 20.1. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market

• 21.1. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 21.2. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Nuclear Medicine Diagnostics Market

• 22.1. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Nuclear Medicine Diagnostics Market

• 23.1. North America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 23.2. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Nuclear Medicine Diagnostics Market

• 24.1. USA Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 24.2. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Nuclear Medicine Diagnostics Market

• 25.1. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 25.2. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Nuclear Medicine Diagnostics Market

• 26.1. South America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 26.2. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market

• 27.1. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market

• 28.1. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 28.2. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Nuclear Medicine Diagnostics Market

• 29.1. Africa Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 29.2. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape
• 30.2. Prostate Cancer Nuclear Medicine Diagnostics Market Company Profiles
  • 30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. General Electric Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

• 31.1. GE Healthcare
• 31.2. Lantheus
• 31.3. CURIUM PHARMA
• 31.4. Telix Pharmaceuticals Ltd.
• 31.5. Eckert & Ziegler AG
• 31.6. Point Biopharma Global Inc.
• 31.7. Point Biopharma
• 31.8. Alliance Medical Ltd.
• 31.9. SHINE Medical Technologies LLC
• 31.10. PETNET Solution
• 31.11. NorthStar Medical Radioisotopes LLC
• 31.12. Global Medical Solutions LLC
• 31.13. Isotope Technologies Garching (ITG)
• 31.14. Jubilant Pharma Limited
• 31.15. Blue Earth Diagnostics Inc.

32. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Nuclear Medicine Diagnostics Market

34. Recent Developments In The Prostate Cancer Nuclear Medicine Diagnostics Market

35. Prostate Cancer Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Prostate Cancer Nuclear Medicine Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate Cancer Nuclear Medicine Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate Cancer Nuclear Medicine Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer